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Growth Hormone Normalizes Low-Density Lipoprotein Receptor Gene 
Expression in Hypothyroid Rats 
Nicoline Hoogerbrugge, Hans Jansen, Bart Staels, Lianne T. Kloet, and Jan C. Birkenh~ger 
Hypothyroidism leads to a decreased activity of the low-density lipoprotein (LDL) receptor, which contributes to the 
hypercholesterolemia frequently seen during hypothyroidism. It is not known whether the decreased activity of the LDL 
receptor is directly due to the absence of thyroid hormone, or secondary to a deficiency of growth hormone {GH). Therefore, the 
effect of GH administration on LDL receptor activity was studied in hypothyroid rats. Following induction of hypothyroidism, 
the level of LDL receptor mRNA was significantly decreased in liver homogenates to 31% _+ 6% of the control value. LDL binding 
to liver cell membranes and plasma membranes decreased during hypothyroidism to approximately 65% of the control value. 
The effect of hypothyroidism on the hepatic LDL receptor was reflected in a significantly increased half.life of 1251-LD/of 29 
hours in controls versus 48 hours in hypothyroid rats. Treatment of hypothyroid rats with human GH (hGH) resulted in 
normalization of both the amount of hepatic LDL receptor mRNA and LDL binding on liver cell membranes. The plasma half-life 
of human lzSl-labeled LDL decreased during GH substitution but did not normalize. GH treatment significantly reduced plasma 
LDL cholesterol levels by 36% (P < .05, n -- 8), to levels that were still higher than in control animals. These data indicate that at 
least part of the decreased LDL receptor activity during hypothyroidism is secondary to GH deficiency. 
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T HE REGULATION OF plasma cholesterol concentra- tion is multifactorial, with age, diet, and hormones 
playing major roles. Hypercholesterolemia is generally 
observed in patients with primary hypothyroidism. TM This 
hypercholesterolemia is caused by an increase in low- 
density lipoprotein (LDL) cholesterol concentration due to 
a reduced LDL receptor activity. 5,6 LDL receptor activity in 
the hypothyroid state normalizes during substitution with 
thyroid hormone. 7 This suggests that thyroid hormone 
stimulates the activity of the LDL receptor. However, 
thyroid hormone is also essential for the production of 
growth hormone (GH). Reduction of GH is shown in 
patients with hypothyroidism. 8,9 Therefore, substitution 
with thyroid hormone will normalize the activity of not only 
thyroid hormone but also GH. It has been shown that GH 
has a profound but not completely understood effect on 
cholesterol metabolism: in hypercholesterolemic adults, 
supraphysiological doses of GH decrease serum choles- 
terol, 1° whereas GH overproduction (as found in acro- 
megaly) is accompanied by low serum cholesterol levels, n
In addition, plasma LDL cholesterol concentration in 
hypothyroid patients shows a negative correlation to the 
activity of GH, reflected in the concentration of plasma 
insulin-like growth factor-I ( IGF-I). 12 Substitution of hy- 
pophysectomized rats with GH decreases plasma LDL 
cholesterol. 13a4 The increase in LDL receptor activity seen 
after substitution with thyroid hormone can be either a 
direct effect of thyroid hormone itself or an indirect effect 
via an increase in GH. 8as In the present study, the effect o f  
GH on LDL receptor activity was determined in hypothy- 
roid rats. 
From the Department of lnternal Medicine IlL University Hospital 
Dijkzigt, Rotterdam, The Netherlands. 
Submitted February 15, 1994; accepted November 13, 1995. 
Address reprint requests o Nicoline Hoogerbrugge, MD, Department 
of Internal Medicine 111, University Hospital Dijkzigt, Dr. Molewater- 
plein 40, 3015 GD Rotterdam, The Netherlands. 
Copyright © 1996 by W..B. Saunders Company 
0026-0495/96/4506-0003503. 00/0 
MATERIALS AND METHODS 
Materials 
Human GH ([hGH] Norditropin) was a generous gift from 
Novo-Nordisk (Gentofte, Denmark). Chow was obtained from Puyk 
Diervoeders (Zutphen, The Netherlands); 2-mercapto-l-methyl- 
imidazole was from Janssen Chimica (Beerse, Belgium); the test kit 
combination, leupeptine and ~-octyl glucoside, was from Boeh- 
ringer (Mannheim, Germany); the IGF-I test kit was from Nichols 
Institute Diagnostics (San Juan Capistrano, CA); and x-ray films 
were from Kodak (Badhoevendorp, The Netherlands). 
Animals and Animal Treatment 
Male Wistar rats weighing 220 --_ 10 g were used. They were 
housed at 21°C on a 12-hour light cycle. To avoid any intake of 
thyroid hormone, the animals were fed a vegetarian diet containing 
a mixture of grains, herbs, and seeds. Chow and drinking water 
were available ad libitum. Hypothyroidism was induced by addition 
of 0.05% (wt/vol) 2-mercapto-l-methyl-imidazole to the drinking 
water, resulting in thyroxine levels less than 1 nmol/L in all animals 
after 14 days of treatment, hGH was administered subcutaneously 
for 10 days twice daily in a daily physiological dose of 0.2 IU/100 g 
body weight dissolved in 0.1 mL 0.9% NaCI. 16,17 Control animals 
were injected twice daily with 0.9% NaC1. On day l0 of substitution 
treatment, animals were killed after an overnight fast. Blood was 
collected in EDTA-containing tubes on ice. Livers were rinsed with 
0.9% NaCI and used immediately for determination of LDL 
receptor activity or frozen in liquid nitrogen and stored at -80°C 
for mRNA analysis. 
Methods 
Total serum cholesterol, rat LDL, rat high-density lipoprotein 
(HDL), and triglycerides were determined as described previ- 
ously. TM Rat LDL (d = 1.019 to 1.050 g/mL) and rat HDL (d = 1.050 
to 1.121 g/mL) were separated by ultracentrifugation f r24 hours 
at 200,000 x g using an SW 41 rotor in a Beckmann L5-50 
ultracentrifuge (Munchen, Germany) and isolated by tube-slicing. 
IGF-I concentration was determined by radioimmunoassay using a 
test kit. Rat GH was determined using a double-antibody radioim- 
munoassay as previously described. TM 
Isolation and labeling of LDL. Human LDL was purified by 
ultracentrifugation (d = 1.019 to 1.063 g/mL) from fresh plasma of 
healthy donors. 19 LDL was labeled with 125I as previously described 
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(specific activity, 100 to 150 cpm/ng LDL protein). 2°,2a The 
iodinated LDL was used within 4 weeks. The free-iodine fraction 
of azsI-labeled LDL samples was less than 1%. 
LDL clearance studies. One hundred micrograms lzsI-LDL 
protein was injected intravenously into the dorsal vein of the penis. 
At various times after injection, tail-tip blood samples (40 IxL) were 
collected in heparinized microhematocrit tubes. The microtubes 
were centrifuged, and 20/~L of the plasma fraction was mixed with 
480 ~L Krebs-Ringer bicarbonate buffer containing 5% bovine 
serum albumin and 500 /xL 10% trichloroacetic acid (TCA). 
Radioactivity was counted (total activity), and then these samples 
were centrifuged for 4 minutes in an Eppendorf centrifuge (Ham- 
burg, Germany) at 14,000 rpm. Intact 125I-LDL was determined by 
subtracting the TCA-soluble fraction from the total radioactivity. 
Kinetic parameters for 125I-LDL turnover were analyzed according 
to the method escribed by Matthews. 22 Initial levels of radioactiv- 
ity in the plasma were adjusted to 100%. The log-linear profiles 
were resolved, and the (log-)linear portion of the curve correspond- 
ing to a period from 21 to 71 hours was fitted to the best 
monoexponential regression curve by the least-square method. The 
slope of this curve was used to determine the half-life of 12SI-LDL. 
The LDL production rate in steady state is equal to the absolute 
catabolic rate, and was calculated from the product of the frac- 
tional catabolic rate (FCR) and plasma LDL levels. 
Determination of LDL receptor activity. Microsomes, endoplas- 
mic reticulum (ER), and plasma membranes were isolated from 
liver homogenates by differential centrifugation i  0.3 mol/L 
sucrose, using a modification of the method described by Aronson 
and Touster. e3 Four volumes of medium (0.3 mol/L sucrose, 10 
mmol/L EDTA, and 1 mol/L 2-mereaptoethanol, pH 7.4) were 
added per gram of liver. The bomogenate was centrifuged for 5 
minutes at 900 x g in a SS 34 rotor. The supernatant was 
centrifuged three times: 10 minutes at 8,700 x g (SS 34 rotor), 10 
minutes at 18,000 x g (SS 34 rotor), and finally 30 minutes at 
200,000 x g (50.2 Ti rotor). The pellet containing the microsomes 
was used for isolation of plasma membranes and ER by gradient 
ultracentrifugation: 1 mL of the pellet was homogenized in 1.5 mL 
57% sucrose. This sample was overlayered with 3 mL 34% sucrose 
and with 1.5 mL 10% sucrose. The tubes were centrifuged for 2.5 
hours at 49,000 rpm in a SW 50.1 Ti rotor. Between the layers with 
34% and 10% sucrose, a white band (plasma membranes) and, 
below it, a red band (ER), appeared. The samples were obtained 
by tube-slicing. Purification of organelles was confirmed by determi- 
nation of the marker enzymes, glucose-6-phosphatase and 5'nucleo- 
tidase for the ER and plasma membranes, respectively (plasma 
membranes showed 5 times higher 5'nucleotidase activity and only 
60% of the glucose-6-phosphatase activity per milligram of protein 
as compared with ER). 
LDL receptor activity was determined by a modification of a 
dot-blot assay as described by Maggi and Catapano. 24 The isolated 
membrane fragments (50 txL) were suspended in50 t~L 50-mmol/L 
Tris maleate, pH 6.5, containing 2 mmol/L CaCI2, 1.5 mmol/L 
PMSF, 0.1 mmol/L leupeptin, and 40 mmol/L t?,-octyl-glucoside. 
The suspension was sonicated, and the undissolved material was 
pelleted by centrifugation for 4 minutes at 10,000 x g. The 
supernatant containing the 13-octyl-glucoside-soluble material was 
diluted with 10 mmol/L Tris hydrochloride (pH 8) containing 50 
mmol/L NaCI and 2 mmol/L CaC12 (buffer B). One hundred 
microliters of the membrane suspension was applied to nitrocellu- 
lose membranes using a manifold apparatus (Bio-Rad, Richmond, 
CA). The amount of protein applied to the nitrocellulose varied 
between 5 and 30 Ixg. The wells were washed three times with 
buffer B (250 IxL). After blocking for 1 hour in buffer B containing 
30 mg/mL bovine serum albumin, the nitrocellulose membrane 
was incubated in buffer B for 16 hours at 4°C with labeled LDL (10 
ixg/mL or as indicated) and then washed five times with buffer B 
and dried for autoradiography. Quantitative analysis of the spots 
was performed using a scanning densitometer. All measurements 
were made in duplicate. Specificity of binding was evaluated in 
several ways: the presence of a 20-fold excess of unlabeled LDL, 
disodium EDTA (30 retool/L), or heparin (4 mg/mL) in the 
incubation medium decreased binding of lzsI-LDL below the level 
of detection. 
LDL receptor mRNA determination. Preparation of RNA from 
the liver of individual animals and dot-blot hybridizations of total 
cellular RNA were performed as described previously. 2s,26 A 
BamHI restriction fragment of the human LDL receptor clone, 
pLDLR-3, corresponding tonucleotide position 1079 to 1450, was 
used as a probe for LDL receptor mRNA determination, e7 A 
chicken 3 actin probe was used as a control zs to normalize for 
effects of differences in the amount of mRNA blotting. Actin 
content did not change by treatment with methimazol r GH (data 
not shown). Filters were hybridized to 1.5 x 106 cpm/mL of each 
probe as previously described. 26Quantitative analysis on autoradio- 
grams of dot-blot filters was performed by scanning densitometry in 
the linear range of film sensitivity. 
Statistical Methods 
The data are presented as the mean ___ SD. ANOVA was used 
for comparison between groups, followed by Bonferroni correc- 
tion. Comparison of linear regression lines was also made using 
ANOVA. 
RESULTS 
Treatment  of rats with methimazol to induce hypothyroid- 
ism led to serum thyroxine concentrat ions below the detec- 
tion level of I nmol/L .  In hypothyroid rats, endogenous GH 
(rGH) and IGF- I  levels decreased significantly to 22% and 
67% of control values, respectively. Body weight remained 
the same over the last 9 days of methimazol  t reatment  
(Table 1). Treatment  of hypothyroid rats with hGH led to 
an increase in plasma IGF- I  concentrat ions to control 
values, whereas rGH level decreased further. Hypothyroid 
GH-t reated animals gained body weight, in contrast o the 
non-GH- t reated  hypothyroid rats (Table 1). 
LDL  Receptor Activity In l, qvo 
Hypothyroidism led to hypercholesterolemia, due to an 
increased concentrat ion of both HDL and LDL cholesterol 
of 54% and 370%, respectively, as compared with control 
levels (Table 2). LDL receptor activity in intact rats was 
studied following the decay of 12SI-LDL. During hypothyroid- 
Table 1. Characteristics of the Different Treatment Groups 
"1"4 rGH }GF-I BWG 
Group (nmol/L} (ng/mL) (U/mL) (g/9 d) 
Control(n=6) 35-+g* 29.9-+ 15.7" 3.36-+0.52" 34-+8" 
Hypothyroid (n = 6) ND 6.7 -+ 4.1 2.25 -+ 0.19 -1 _+ 4 
Hypothyroid + GH 
(n = 8) ND 3.7 -+ 2.5 3.64 - 0.36* 9 -+ 2* 
Abbreviations: T4, thyroxine; BWG, body weight gain; ND, not 
detectable, 





Group Total LDL HDL Triglycerides 
Control 
(n = 6) 2.31 _+ 0.21" 0.31 _+ 0.04* 1.52 _+ 0.12" 1,08 + 0.25* 
Hypothroid 
(n = 6) 4.21 +- 0.48 1.46_+ 0.11 2.34 +_ 0.47 0.55-+ 0.13 
Hypothyroid + 
GH(n=8)  3.48_+0.29" 0.93-+0.24" 2.06_+0.10 0.65-+0.20 
*P < .05 v hypothyroid rats. 
ism, the half-life of plasma 125I-LDL increased significantly 
from 29 hours in controls to 48 hours in hypothyroid rats 
(P < .05, n = 4). After treatment with hGH, the decay of 
z25I-LDL was increased, with a half-life of 41 hours. The 
decay curve of GH-treated rats was significantly different 
from that of hypothyroid rats (P < .05, n = 4), but the 
half-life was still significantly less than in controls (Fig 1). 
These changes in half-life were paralleled by changes in the 
FCR (Table 3). On the other hand, the LDL production 
rate was significantly higher in hypothyroid rats as com- 
pared with controls (21 and 10 i~mol/L/h, respectively, P < 
.01, n -- 4; Table 3). After hGH treatment, he ACR was 
not changed as compared with the rate in untreated hypo- 
thyroid rats (20 p, mol/L/h, n = 4; Table 3). In hypothyroid 
rats, the increased production and decreased LDL removal 
rate results in a largely increased plasma LDL cholesterol 
content (Table 2). During GH treatment, he LDL removal 
rate is partly restored but the production rate is unaffected, 
reflected in a small decrease in plasma LDL concentration 
(P < .05, n = 8). 
Fig 1. 
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Plasma clearance of human 12SI-LDL in hypothyroid rats is 
significantly reduced as compared with controls (P < .01). Substitu- 
tion treatment of hypothyroid rats with GH increased the LDL 
clearance rate (P < .05) but did not normalize it. Symbols represent 
the mean -+ SD. (11) Controls, (17) hypothyroid rats treated with GH, 
and (©) hypothyroid rats. 
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Table 3. Kinetic Parameters for lzSI-LDL Turnover in Normal, 
Hypothyroid, and GH-Treated Hypothyroid Rats 
ACR 
Group Half-Life (h) FCR (pools/h) (mmol/h/L plasma) 
Control (n = 4) 28.5 -+ 3,4 0.028 + 0.005 0.010 +- 0.001 
Hypothyroid (n = 4) 47.7 + 6.7* 0.017 +- 0.003* 0.021 +- 0.004* 
Hypothyroid + GH 
(n = 4) 40.9 -+ 3.9* 0.020 -+ 0.002* 0.020 +- 0.002* 
NOTE. The ACR is equal to the product of the FCR and plasma LDL 
levels. In steady state, the ACR is equal to the LDL production rate. 
Kinetic parameters were calculated as described by Matthews. 22 
Abbreviation: ACR, absolute catabolic rate. 
*P < .05 v control values. 
Hepatic LDL Receptor Activity In Vitro 
The effect of GH replacement on hepatic LDL receptor 
activity was studied using a ligand dot-blot assay. I25I-LDL 
was used as the ligand for binding to microsomal fractions 
isolated from control, hypothyroid, and hypothyroid GH- 
treated rats. With different amounts of microsomes contain- 
ing between 5 and 15 ~g protein, specific LDL binding 
increased linearly with the amount of microsomes used (Fig 
2). Microsomes isolated from hypothyroid rats contained, 
on a protein basis, the lowest LDL binding capacity. LDL 
binding to microsomes from control and GH-treated hypo- 
thyroid animals was similar. Optimal LDL binding occurred 
at LDL concentrations above 5 ixg/mL. Saturation curves 
with microsomes of control and GH-treated hypothyroid 
rats were similar, indicating that these microsomes con- 
tained the same number of LDL receptors with the same 
affinity for 125I-LDL (data not shown). To prove that the 
observed normalization i LDL binding after GH treatment 
in microsomes represented an increase in LDL receptor 
plasma membrane level, a plasma membrane-enriched 






Table 2. Effects of GH Treatment on Plasma Lipid Concentrations 
(retool/L) in Hypothyroid Rats 
Membrane Protein (ug) 
Fig 2. 12SI-LDL binding to liver microsomes as a function of the 
concentration of membrane protein. Each point is the mean + SD 
triplicate determinations. (11) Controls, (FI) hypothyroid rats treated 
with GH, and {©) hypothyroid rats. 
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to plasma membranes was 140% _+ 16% of the amount 
bound to the same amount of microsome protein. Using 
these plasma membranes in a dot-blot assay, it was shown 
that LDL binding capacity was completely restored by GH 
treatment (data not shown). These results show that GH 
treatment of hypothyroid rats leads to a normalization of 
the amount of LDL receptors in the liver. 
Hepatic LDL Receptor mRNA 
Hepatic LDL receptor mRNA levels were measured to 
determine the level at which the induction of LDL receptor 
activity by GH takes place, mRNA for the LDL receptor in 
hypothyroid rats was decreased to 31% -+ 6% of control 
level. GH treatment of hypothyroid rats led to a complete 
restoration of LDL mRNA levels to control values 
(102% -+ 10%; Fig 3). These results uggested that GH may 
abolish the effects of hypothyroidism on the LDL receptor. 
DISCUSSION 
Plasma LDL cholesterol is increased uring hypothyroid- 
ism. In hypothyroid rats, we found a diminished clearance 
rate of 125I-LDL and a decreased LDL binding capacity of 
the liver. The LDL receptor mRNA level was also dimin- 
ished, suggesting that during hypothyroidism hypercholes- 
terolemia is caused by reduced hepatic LDL receptor gene 
expression. This effect can be caused either by a deficiency 
of thyroid hormone or by the concomitant decrease in GH 
activity. We showed that GH substitution of hypothyroid 
rats resulted in a normalization both of LDL receptor 
mRNA and of LDL binding capacity in the liver. This 
indicates that LDL receptor activity is stimulated by GH. 
However , plasma LDL cholesterol and the rate of LDL 
clearance did not normalize in GH-treated hypothyroid 
mRNA 
LDL-receptor 
rats. A discrepancy existed between GH treatment effects 
on LDL receptor gene expression versus its effects on LDL 
cholesterol concentration. 
The observed iscrepancy may result from an enhanced 
LDL production rate in hypothyroidism, as shown previ- 
ously. 3 We confirmed this finding and showed that the 
increased production rate was not affected by the substitu- 
tion of GH. Another explanation can be found in a 
decreased membrane fluidity, which has been shown during 
hypothyroidism. 29 The stiffer membranes might interfere 
with internalization or recycling of the LDL receptor. In 
such a situation, even a normal amount of LDL receptors 
can result in a less efficient catabolism. The lack of effect of 
GH on LDL cholesterol concentration could not be ex- 
plained by nonfunctioning intracellular LDL receptors, 
since we showed that GH also normalized LDL receptor 
activity in isolated plasma membranes. The experimental 
model we used is different from the actual situation , since 
labeled human LDL was used in rats. Human LDL may not 
represent in vivo LDL clearance, since human LDL binds 
to the LDL receptor with a lower affinity than apo E--con- 
taining rat LDL. 3°,3~ Therefore, human LDL has to com- 
pete with the apo E-containing endogenous rat LDL, which 
could result in an apparently lower clearance rate. How- 
ever, human LDL was used both for binding studies and for 
the determination f clearance rate, and cannot explain the 
above-mentioned discrepancy. Moreover, it was shown by 
others that human 12SI-LDL can be used as a model to study 
the LDL receptor, having important features in common 
with the binding of native LDL. 32-34 
Whatever the reason for the discrepancy between the 
LDL concentration and the hepatic LDL receptor activity, 
our results demonstrate unambiguously that GH affects 
controls 
hypothyroids 
hypoth + GH 
| I 
0 50 100 
% of control value 
Fig 3. Effects of hypothyroidism and GH treatment of hypothyroid rats on mRNA for the LDL receptor for groups of 4 rats, Symbols represent 
the mean +- SD. 
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LDL receptor gene expression at the mRNA level: It can be 
concluded that at least part of the effect of hypothyroidism 
on LDL metabolism is due to the concomitant GH deft- 
ciency, 
In the LDL receptor gene, a thyroid-responsive el ment 
has never been found, but it appeared to be present in the 
gene coding for GH. 35 In hypophysectomized rats, with no 
GH production, it was shown by others that the hepatic 
LDL receptor mRNA level could only be elevated by very 
high doses of triiodothyronine. This mRNA level appeared 
to increase much slower than other well-known thyroid 
hormone-sensitive enzymes like 7~-reductase. 36 This sug- 
gests that thyroid hormone might activate the gene coding 
for GH, resulting in GH activity, while GH affects the LDL 
receptor. Our results do not exclude a direct effect of 
thyroid hormone on LDL receptor activity. It has been 
shown that thyroid hormone has a stimulating effect on 
LDL catabolism. 5-7 However, some of the cell culture 
experiments were performed in the presence of fetal calf 
serum (FCS) and may show the joint effect of thyroid 
hormone and GH. FCS contains ome GH, but especially 
IGF-I in a sufficient concentration. We measured a GH 
concentration of approximately 0.2 Ixg/L and an IGF-I 
concentration between 7 and 36 nmol/L, in FCS batches. 
Therefore, the contribution of thyroid hormone (or lack of 
it) to LDL cholesterol metabolism is difficult o assess from 
such experiments. 
GH activity can be exerted by GH itself or via IGF-I. In 
our study with GH-treated hypothyroid rats, an increase in 
plasma IGF-I was shown, and endogenous rGH concentra- 
tion decreased further as compared with levels in hypothy- 
roid rats. These data suggest that the stimulating effect of 
GH on LDL receptor activity may be mediated by IGF-I. 
Support for this theory has been found in patients with 
Laron-type dwarfism. Patients with Laron-type dwarfism 
are characterized by high plasma levels of GH and an 
inability to generate ndogenous IGF-I, due to a GH 
receptor defect. In these patients, administration f IGF-I 
causes a decrease in plasma cholesterol concentration. 3v 
Also, in healthy men, a decrease in cholesterol was shown 
after IGF-I injections. 3sThis suggests that the hypocholes- 
terolemic effect of GH can be mediated by IGF-I. 
The present study shows a stimulating role for GH in 
LDL metabolism. This contribution is relevant both for 
primary GH deficiency and for hypothyroidism. There is 
evidence now that GH may modulate hepatic responsive- 
ness to the action of several other hormones, like thyroid 
hormone and estrogen. Recently, Rudling et a139 showed in 
estrogen-treated rats that GH was needed for the stimulat- 
ing effect of estrogen on the LDL receptor. This permissive 
function of GH was also found in other components of lipid 
metabolism. In hypophysectomized rats, we have shown 
that hepatic lipase activity could only be stimulated by 
thyroid hormone during substitution ofGH. 14 
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